Monthly Prescribing Reference

Vesicare Ls

Solifenacin succinate 1mg/mL; oral susp; orange-flavor. Take once daily, followed by liquid (eg, water or milk). Avoid taking at the same time with food or other drinks. Missed dose: take as soon as ...
EurekAlert!

New data on Vesicare show significant improvements in urgency for patients with overactive bladder

Vesicare is the first overactive bladder treatment at an approved dose to show a statistically significant increase in warning time before urination Christchurch, New Zealand – December 1, 2006 – ...
Monthly Prescribing Reference

Vesicare LS Approved for Neurogenic Detrusor Overactivity

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.
Pharmabiz

US FDA approves Astellas Pharma’s VESIcare LS for treatment of bladder dysfunction in children ages two years and older

The US Food and Drug Administration (FDA) granted approval to VESIcare LS (solifenacin succinate) oral suspension, a liquid taken by mouth, for the treatment of neurogenic detrusor overactivity (NDO), ...